Related to Gamida Cell Raises $10M to Progress Phase III-Stage Hematologic Cancer Cell Therapy

• URMC Gets $15M to Study Homspera as a Radiation-Induced Injury Countermeasure
  
• Novartis Pays Incyte $50M on Start of Phase III Trial with INCB18424 for Polycythemia Vera
  
• First Patient Receives ReNeuron’s Neural Stem Cell Therapy
  
• StemCells Snags Swissmedic OK to Start Neural Stem Cell Trial in Spinal Cord Injury
  
• Cephalon Shells Out $350M to Commercialize Mesoblast Stem Cell Therapies
  
• Researchers Find Extended Culturing of Engineered iPSCs Doesn’t Increase Mutations
  
• Plasticell Spins Out Progenitor Labs for Regenerative Drug Discovery
  
• U.S. Army Institute of Surgical Research Taps Arteriocyte for Orthopedic Trauma Cellular Therapies
  
• Pharmacyclics Secures Five-Year CRADA with NCI to Develop Blood Cancer Drug
  
• Qiagen and Lilly to Co-Develop Companion Diagnostic for JAK2 Inhibitor Candidate
  
• Cardio3 Establishes U.S. Subsidiary in Advance of Phase III Heart Failure Cell Therapy Trial
  
• Cellerix Secures €4.95M for Phase III Study of Allogeneic Adult Stem Cell Therapy
  
• FDA Sanctions NYBC’s Cord Blood Hematopoietic Progenitor Cells for Transplantation
  
• First Clinical Trial of Autologous Cardiac Stem Cells Shows Positive Results
  
• Geron Sidelines Stem Cell Programs and Cuts Workforce to Focus on Clinical Cancer Candidates
  
• Mundipharma Commits $50M to Infinity’s PI3K Inhibitor Program in 2013
  
• Studies Show MSCs Can Deliver shRNAs to Inhibit Huntington Disease Protein
  
• Sistemic Joins €5.9M TiGenix-Led EU Consortium to Develop Stem Cell Rheumatoid Arthritis Therapy
  
• Cytomedix Picks Up Stem Cell Therapy Firm Aldagen
  
• AlloCure Pockets $25M for Acute Kidney Injury Stem Cell Therapy